Fresenius Medical Care AG & Co. KGaA
NYSE:FMSMedical - Care Facilities
-$0.18 today
- Market cap
- $11.26B
- Beta
- 0.81
- P/E (TTM)
- 11.9
- EPS (TTM)
- $3.43
- Dividend yield
- 3.65%
Volume 1.92M
Average 0.72M
FMS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Fresenius Medical Care AG & Co. KGaANYSE: FMS
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of €39.63M rose 4.0% year over year, ahead of the -10.1% change in trailing-twelve-month research & development. Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at -11.6% a year.
Context
- Research & development amounted to 0.8% of revenue in FY2025, down 0.1 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +4.0% holds above the trailing-twelve-month pace of -10.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 157.98M EUR
- Year-over-year change
- -13.9%
- 4-year CAGR
- -8.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 157.98M | -13.9% |
| FY2024 | 2024-12-31 | 183.49M | -20.9% |
| FY2023 | 2023-12-31 | 231.97M | +1.5% |
| FY2022 | 2022-12-31 | 228.62M | +3.6% |
| FY2021 | 2021-12-31 | 220.78M | — |
Research & Development vs competitors
How FMS compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.1% is the lowest of 3, against a peer median of +47.5%.
- Research & development amounts to 0.8% of revenue for FMS, versus a peer median of 28.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $245.55M USD | +16.8% | -3.2% | 37.7% | |
| LTM Jun 2026 | €154.32M EUR | -10.1% | -11.6% | 0.8% | |
| LTM Mar 2026 | $67.09M USD | +78.1% | -27.8% | 28.9% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding FMS) | — | +47.5% | -15.5% | 28.9% | |
Competitors are the stored peer set for FMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.62B | 19.4B | 19.45B | 19.34B | 19.63B |
| Cost of Revenue | 12.85B | 14.5B | 14.53B | 14.58B | 14.6B |
| Gross Profit | 4.77B | 4.89B | 4.93B | 4.76B | 5.03B |
| Gross Margin | 27.1% | 25.2% | 25.3% | 24.6% | 25.6% |
| Research & Development | 220.78M | 228.62M | 231.97M | 183.49M | 157.98M |
| Selling, General & Admin | 2.77B | 3.17B | 3.2B | 3.14B | 3.03B |
| Operating Expenses | 2.92B | 3.38B | 3.56B | 3.29B | 3.2B |
| Depreciation & Amortization | 1.62B | 1.84B | 1.75B | 1.74B | 1.5B |
| EBITDA | 3.55B | 3.42B | 3.21B | 3.21B | 3.4B |
| EBITDA Margin | 20.1% | 17.6% | 16.5% | 16.6% | 17.3% |
| Operating Income | 1.85B | 1.51B | 1.37B | 1.47B | 1.83B |
| Operating Margin | 10.5% | 7.8% | 7.0% | 7.6% | 9.3% |
| Interest Income | 73.17M | 67.66M | 88.22M | 71.58M | 69.61M |
| Interest Expense | 353.6M | 360.14M | 424.64M | 407.04M | 384.41M |
| Other Income / Expenses | (280.43M) | (292.48M) | (336.42M) | (410.45M) | (314.59M) |
| Income Before Tax | 1.57B | 1.22B | 1.03B | 1.06B | 1.51B |
| Pre-Tax Margin | 8.9% | 6.3% | 5.3% | 5.5% | 7.7% |
| Income Tax Expense | 352.83M | 324.95M | 300.56M | 316.06M | 320.97M |
| Net Income | 969.31M | 673.41M | 499M | 537.91M | 978.37M |
| Net Margin | 5.5% | 3.5% | 2.6% | 2.8% | 5.0% |
| EPS (Basic) | 0.83 | 0.57 | 0.85 | 0.92 | 1.68 |
| EPS (Diluted) | 0.83 | 0.57 | 0.85 | 0.92 | 1.68 |
| Weighted Avg Shares | 1.17B | 1.17B | 586.83M | 586.83M | 582.38M |
| Weighted Avg Shares (Diluted) | 1.17B | 1.17B | 586.83M | 586.83M | 582.38M |
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
Intrinsic Alpha fair value
Locked
Current Price
$20.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.